Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?

M. Galuppo, E. Mazzon, S. Giacoppo, O. Bereshchenko, S. Bruscoli, C. Riccardi, P. Bramanti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.

Original languageEnglish
Pages (from-to)990-993
Number of pages4
JournalCurrent Molecular Medicine
Volume15
Issue number10
Publication statusPublished - Dec 1 2015

Fingerprint

Catenins
Multiple Sclerosis
Wnt Signaling Pathway
Natalizumab
Blood Cells
Blood
Western Blotting
Chemical activation
Pharmacology
Therapeutics

Keywords

  • First diagnosis patients
  • Interferon-beta
  • Natalizumab
  • Neurodegenerative disease
  • Relapsing/remitting multiple sclerosis
  • Wnt/β-catenin pathway

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Galuppo, M., Mazzon, E., Giacoppo, S., Bereshchenko, O., Bruscoli, S., Riccardi, C., & Bramanti, P. (2015). Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action? Current Molecular Medicine, 15(10), 990-993.

Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action? / Galuppo, M.; Mazzon, E.; Giacoppo, S.; Bereshchenko, O.; Bruscoli, S.; Riccardi, C.; Bramanti, P.

In: Current Molecular Medicine, Vol. 15, No. 10, 01.12.2015, p. 990-993.

Research output: Contribution to journalArticle

Galuppo, M, Mazzon, E, Giacoppo, S, Bereshchenko, O, Bruscoli, S, Riccardi, C & Bramanti, P 2015, 'Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?', Current Molecular Medicine, vol. 15, no. 10, pp. 990-993.
Galuppo M, Mazzon E, Giacoppo S, Bereshchenko O, Bruscoli S, Riccardi C et al. Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action? Current Molecular Medicine. 2015 Dec 1;15(10):990-993.
Galuppo, M. ; Mazzon, E. ; Giacoppo, S. ; Bereshchenko, O. ; Bruscoli, S. ; Riccardi, C. ; Bramanti, P. / Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?. In: Current Molecular Medicine. 2015 ; Vol. 15, No. 10. pp. 990-993.
@article{3c202cdeb4d3407aa898295be7e5ea8d,
title = "Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?",
abstract = "Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.",
keywords = "First diagnosis patients, Interferon-beta, Natalizumab, Neurodegenerative disease, Relapsing/remitting multiple sclerosis, Wnt/β-catenin pathway",
author = "M. Galuppo and E. Mazzon and S. Giacoppo and O. Bereshchenko and S. Bruscoli and C. Riccardi and P. Bramanti",
year = "2015",
month = "12",
day = "1",
language = "English",
volume = "15",
pages = "990--993",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?

AU - Galuppo, M.

AU - Mazzon, E.

AU - Giacoppo, S.

AU - Bereshchenko, O.

AU - Bruscoli, S.

AU - Riccardi, C.

AU - Bramanti, P.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.

AB - Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.

KW - First diagnosis patients

KW - Interferon-beta

KW - Natalizumab

KW - Neurodegenerative disease

KW - Relapsing/remitting multiple sclerosis

KW - Wnt/β-catenin pathway

UR - http://www.scopus.com/inward/record.url?scp=84959466570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959466570&partnerID=8YFLogxK

M3 - Article

C2 - 26592242

AN - SCOPUS:84959466570

VL - 15

SP - 990

EP - 993

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 10

ER -